-
tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name
Zevalin, is a
monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's...
- anaphylaxis,
neutropenia (low neutrophils), and
thrombocytopenia (low platelet).
Zevalin,
another radioligand therapy that
targets non-Hodgkin
lymphoma CD20 ligand...
- sold for
about $25,000 for one
round of treatment.
Bexxar competed with
Zevalin,
until the former's
discontinuation in 2014. A
personalized regimen using...
-
iodide Hyperthyroidism and
thyroid cancer Yttrium-90-ibritumomab
tiuxetan (
Zevalin) and Iodine-131-tositumomab (Bexxar)
Refractory lymphoma 131I-MIBG...
-
States Food and Drug
Administration (FDA)
approved ibritumomab tiuxetan (
Zevalin),
which is an anti-CD20
monoclonal antibody conjugated to yttrium-90. In...
- doi:10.1038/nrd1413. PMID 15173838. S2CID 22166498.
FIbritumomab Tiuxetan (
Zevalin™)
Radioimmunotherapy of Non-Hodgkin’s
Lymphoma Rao AV,
Akabani G, Rizzieri...
- two rare disorders". FDA.
Retrieved 2011-04-19. "Cell
Therapeutics buys
Zevalin from
Biogen Idec for $10M, with up to $20M
extra plus milestones". The...
-
human PD-1
squamous cell non-small cell lung
cancer Ibritumomab tiuxetan Zevalin mab
mouse CD20 Y non-Hodgkin's
lymphoma Icru****ab mab
human VEGFR-1 cancer...
-
thyroid cancer, and
radioimmunotherapy with 90Y
ibritumomab tiuxetan (
Zevalin) & 131I
tositumomab (Bexxar)
therapy of low-grade non-Hodgkin's lymphoma...
- process,
which is
tailored to the
desired product.
Ibritumomab Tiuxetan;
Zevalin - For
dosimetry estimates prior to 90Y
immunotherapy for
lymphoma 111In...
